Rizatriptan in the Treatment of Menstrual Migraine

Silberstein, Stephen D.; Massiou, H.; Jeunne, Claire Le; Johnson-Pratt, Lisa; McCarroll, Kathleen

doi:10.1097/00006250-200008000-00016

Cited by 32 publications

(54 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At variance with the literature (30)(31)(32)(33)(34)(35)(36), perimenstrual attacks, in particular MA, seemed in our study to be less responsive than NMA to acute attack treatment. Even though our study was not a randomized controlled trial, and therefore the results must be treated with caution, we believe that they may reflect a real relative refractoriness of perimenstrual attacks to symptomatic drugs, at least in severely affected MRM patients.…”

Section: Discussioncontrasting

confidence: 99%

Characteristics of Menstrual and Nonmenstrual Attacks in Women with Menstrually Related Migraine Referred to Headache Centres

et al. 2004

View full text Add to dashboard Cite

Aim of this study was to determine whether menstrual attacks differ from nonmenstrual attacks (NMA) as regards clinical features or response to abortive treatment in women affected by menstrually related migraine (MRM) referred to tertiary care centres. Sixty-four women with MRM were enrolled in a 2-month diary study. Perimenstrual attacks were split into three groups--premenstrual (PMA), menstrual (MA) and late menstrual (LMA)--and compared to nonmenstrual ones. Perimenstrual attacks were significantly longer than NMA. No other migraine attack features were found to differ between the various phases of the cycle. Migraine work-related disability was significantly greater in PMA and MA than in NMA. Acute attack treatment was less effective in perimenstrual attacks. Pain-free at 2 h after dosage was achieved in 13.5% of MA (OR 0.41; 95% CI 0.22, 0.76) vs. 32.9% of NMA. We concluded that, in MRM, perimenstrual attacks are longer and less responsive to acute attack treatment than NMA.

show abstract

Section: Discussioncontrasting

confidence: 99%

Characteristics of Menstrual and Nonmenstrual Attacks in Women with Menstrually Related Migraine Referred to Headache Centres

et al. 2004

View full text Add to dashboard Cite

show abstract

“…The current substudy examined the efficacy of rizatriptan 10 mg in the treatment of menstrual There is a perception that menstrual migraine is more painful, longer lasting, and more difficult to treat than migraines occurring at other times of the month. [13][14][15][16] In a recent study of 155 women in a specialized migraine clinic, MacGregor and Hackshaw 17 found that the risk of migraine was greater during the perimenstrual period and that women reported menstrual migraine as more likely to be severe and associated with nausea and vomiting. Granella et al 18 studied women with MRM who were referred to tertiary care centers and reported that attacks during the perimenstrual period were longer, more intense, and less responsive to analgesics.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Rizatriptan for Menstrual Migraine in an Early Intervention Model: A Prospective Subgroup Analysis of the Rizatriptan TAME (Treat A Migraine Early) Studies

Martin

Cady²,

Mauskop³

et al. 2007

Headache

View full text Add to dashboard Cite

show abstract

“…Rizatriptan.-Silberstein et al reported the results of a retrospective study of oral rizatriptan 10 mg, administered when headache pain was moderate to severe. 4 At 2 hours after dosing, 68% of 139 women had pain relief compared with 44% of 81 women receiving placebo (P < .05).…”

Section: Acute Treatmentmentioning

confidence: 95%

“…Acute treatment with triptans has been shown to have similar efficacy in menstrual and nonmenstrual migraines. [4][5][6] However, some women may find the level of disability associated with MM to be unacceptable, despite acute therapy. Fortunately, the predictable nature of MM lends itself to short-term prevention strategies.…”

mentioning

confidence: 99%

Tailoring Management Strategies for the Patient With Menstrual Migraine: Focus on Prevention and Treatment

Tepper

2006

Headache

View full text Add to dashboard Cite

Many women report an increased frequency of headaches around the time of menses. For some women, these headaches are more severe, of longer duration, and lead to greater disability than those occurring at other times in the menstrual cycle. A headache diary is critical to properly diagnose menstrual migraine (MM) by prospectively documenting headache days, severity of headache, and the headaches' relationship to menses. In women with diagnosed MM, acute treatment has been proven to be effective in randomized clinical trials. For those women who have predictable periods and may require preventive therapy, short-term prevention is a reasonable approach due to the predictability of MM. Although several agents (eg, naproxen sodium, magnesium, triptans) have been evaluated for prevention of MM, all but triptans have been assessed in small trials of between 20 and 35 women. Naratriptan, frovatriptan, and, most recently, zolmitriptan have been proven effective in preventing MM. Triptans are generally well tolerated, and the long-term safety of these agents is currently being evaluated. The flexibility of using acute and preventive therapy allows physicians to tailor treatment of MM and meet the needs of individual patients.

show abstract

Rizatriptan in the Treatment of Menstrual Migraine

Cited by 32 publications

References 18 publications

Characteristics of Menstrual and Nonmenstrual Attacks in Women with Menstrually Related Migraine Referred to Headache Centres

Characteristics of Menstrual and Nonmenstrual Attacks in Women with Menstrually Related Migraine Referred to Headache Centres

Efficacy of Rizatriptan for Menstrual Migraine in an Early Intervention Model: A Prospective Subgroup Analysis of the Rizatriptan TAME (Treat A Migraine Early) Studies

Tailoring Management Strategies for the Patient With Menstrual Migraine: Focus on Prevention and Treatment

Contact Info

Product

Resources

About